NFE2L2 and cancer: KEAP1, MCM3, and NRF2 interactions seem to be part of some complex regulatory mechanisms, and those interactions could be exploited in cancer therapy and perhaps against altered MCM3 to inhibit NRF2 function or DNA replication process by this protein in cancers [60,67].